In patients with rheumatoid arthritis (RA) not controlled on methotrexate (
MTX) alone, clinical trials have shown that combination therapy with cyclos
porine (CSA) and MTX is effective and relatively well tolerated over 12 mon
ths. Information regarding the long-term benefits, toxicities and tolerabil
ity of this combination therapy in clinical practice, and comparisons with
alternative strategies, will determine the utility of the MTX plus CSA comb
ination regimen in patients with RA not controlled with a single drug.